Among the molecules directly targeting inflammation in clinical trials in phase 2/3 [inhibition of plasma Amine Oxidase Copper-containing 3 (BI 1467335, Boehringer, phase 2) and Galectin 3, a lectin family member (GR-MD-02, Galectin Therapeutics, phase 2)], only CVC (CCR2/CCR5 antagonist, Allergan) is currently under evaluation in a phase III trial in fribrotic NASH patients. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.